References
- WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2022. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020. Accessed May 7, 2021.
- Places without reported COVID-19 cases. https://www.usnews.com/news/best-countries/slideshows/countries-without-reported-covid-19-cases. Accessed May 7, 2021.
- Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B, et al. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. Muscle Nerve. 2020;62:182–6.
- Vasta R, Moglia C, D’Ovidio F, Di Pede F, Filippo De Mattei F, Sara Cabras S, et al. Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:308– 4. 308–311.
- Conduct of clinical trials of medical products during the COVID-19 public health emergency. https://www.fda.gov/media/136238/download Accessed May 8, 2021.
- Guidance on the management of clinical trials during the COVID-19 (coronavirus) Pandemic. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf Accessed May 8, 2021.
- Pulmonary function laboratories: advice regarding COVID-19. https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-laboratories.php Accessed May 8, 2021.
- European Respiratory Society (ERS) Recommendations on lung function testing during the COVID-19 pandemic and beyond. https://blacklungcoe.org/european-respiratory-society-ers-recommendations-on-lung-function-testing-during-the-covid-19-pandemic-and-beyond/ Accessed May 8, 2021.
- Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2005;77:390–2.
- Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al.; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
- Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, et al. Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81:2136–40.
- Qualification process for drug development tools. https://www.fda.gov/media/133511/download Accessed May 9, 2021.
- Clinical outcome assessment (COA) qualification program: frequently asked questions. https://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessment-coa-qualification-program-frequently-asked-questions Accessed May 9, 2021.
- Walton MK, Powers JH, 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, et al. Clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment - emerging good practices for outcomes research task force. Value Health. 2015;18:741–52.
- ICH reflection paper on proposed ICH guideline work to advance patient focused drug development. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf Accessed May 10, 2021.
- Goodsaid F, Papaluca M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol. 2010;28:441–3.
- Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther. 2015;98:34–46.